# US 2015/0147277 A1 · Compositions and methods for assessing gut function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147277 A1
- Document ID: US20150147277A1
- Status: Published application
- Kind: A1
- Application number: 14/538,770
- Filed: 2014-11-11
- Published: 2015-05-28
- Earliest claimed: 2013-11-11
- Assignees: MediBeacon Inc.
- Inventors: Richard B. Dorshow; Steven J. Hanley; Phillip I. Tarr
- Web page: https://patentgrep.com/patent/US20150147277A1

## CPC

- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61K 31/497: containing further heterocyclic rings
- A61K 49/0021: {the fluorescent group being a small organic molecule}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

## Claims

### Claim 1

A composition for assessing gut function in a subject in need thereof, comprising a fluorescent challenge molecule, wherein the fluorescent challenge molecule is not substantially absorbed by a healthy gut.

### Claim 2

A method for assessing gut function in a subject in need thereof, comprising the steps of:
a. administering an effective amount of a composition for assessing gut function, comprising a fluorescent challenge molecule, wherein the fluorescent challenge molecule is not substantially absorbed by a healthy gut into the subject's gut;
b. irradiating the composition absorbed by the subject's gut with non-ionizing radiation, wherein the radiation causes the composition to fluoresce;
c. detecting the fluorescence of the fluorescent challenge molecule; and
d. assessing gut function in the subject based on the detected fluorescence.

### Claim 3 (depends on 2)

The method of claim 2, wherein the composition is administered orally.

### Claim 4 (depends on 2)

The method of claim 2, wherein the non-ionizing radiation has a wavelength of at least 350 nm.

### Claim 5 (depends on 2)

The method of claim 2, wherein the composition absorbed by the subject's gut is irradiated and detected in the subject's skin, blood, urine, or fascia.

### Claim 6 (depends on 2)

The method of claim 2, wherein the composition absorbed by the subject's gut is irradiated and detected transcutaneously.

### Claim 7 (depends on 2)

The method of claim 2, wherein the detected fluorescence of the fluorescent challenge molecules is measured over time.

### Claim 8

A method for assessing gut function in a subject in need thereof, comprising the steps of:
a. administering an effective amount of a composition comprising two fluorescent challenge molecules, wherein the first fluorescent challenge molecule is not substantially absorbed by a healthy gut, and wherein the second fluorescent challenge molecule is substantially absorbed by a healthy gut into the subject's gut;
b. irradiating the composition absorbed by the subject's gut with non-ionizing radiation, wherein the radiation causes the composition to fluoresce;
c. detecting the fluorescence of each fluorescent challenge molecule in the composition; and
d. assessing gut function in the subject based on the detected fluorescence.

### Claim 9 (depends on 8)

The method of claim 8, wherein the composition is administered orally.

### Claim 10 (depends on 8)

The method of claim 8, wherein the non-ionizing radiation has a wavelength of at least 350 nm.

### Claim 11 (depends on 8)

The method of claim 8, wherein the composition absorbed by the subject's gut is irradiated and detected in the subject's skin, blood, urine, or fascia.

### Claim 12 (depends on 8)

The method of claim 8, wherein the composition absorbed by the subject's gut is irradiated and detected transcutaneously.

### Claim 13 (depends on 8)

The method of claim 8, wherein gut function is assessed by comparing the detected fluorescence of the fluorescent challenge molecule that is not substantially absorbed by a healthy gut to the fluorescent challenge molecule that is substantially absorbed by a healthy gut.

### Claim 14 (depends on 8)

The method of claim 8, wherein the detected fluorescence of the fluorescent challenge molecules is measured over time.

### Claim 15

A method of assessing the location of a disease or an injury in a subject's gut, comprising the steps of:
a. administering an effective amount of a composition comprising two fluorescent challenge molecules, wherein the first fluorescent challenge molecule is not substantially absorbed by a healthy gut, and wherein the second fluorescent challenge molecule is substantially absorbed by a healthy gut into the subject's gut;
b. irradiating the composition absorbed by the subject's gut with non-ionizing radiation, wherein the radiation causes the composition to fluoresce;
c. detecting the fluorescence of each fluorescent challenge molecule in the composition over time; and
d. assessing the location of disease or injury in the subject's gut, based on the time between the detected fluorescence of each fluorescent challenge molecule and administration.

### Claim 16 (depends on 15)

The method of claim 15, wherein the composition is administered orally.

### Claim 17 (depends on 15)

The method of claim 15, wherein the non-ionizing radiation has a wavelength of at least 350 nm.

### Claim 18 (depends on 15)

The method of claim 15, wherein the composition absorbed by the subject's gut is irradiated and detected in the subject's skin, blood, urine, or fascia.

### Claim 19 (depends on 15)

The method of claim 15, wherein the composition absorbed by the subject's gut is irradiated and detected transcutaneously.

### Claim 20 (depends on 15)

The method of claim 15, wherein the detected fluorescence of the challenge molecule that is not substantially absorbed by a healthy gut occurs before or substantially simultaneously as compared the detected fluorescence of the challenge molecule that is substantially absorbed by a healthy gut indicates that the disease or injury is located in the proximal portion of the gut.

### Claim 21 (depends on 20)

The method of claim 20, wherein the disease or injury located in the proximal portion of the gut is Celiac disease.

### Claim 22 (depends on 15)

The method of claim 15, wherein the detected fluorescence of the challenge molecule that is not substantially absorbed by a healthy gut occurs substantially later in time as compared the detected fluorescence of the challenge molecule that is substantially absorbed by a healthy gut indicates that the disease or injury located in the distal portion of the gut.

### Claim 23 (depends on 22)

The method of claim 22, wherein the disease or injury located in the proximal portion of the gut is ulcerative colitis.

### Claim 24

A kit for assessing gut function in a subject in need thereof, comprising:
a. a composition for assessing gut function, comprising a fluorescent challenge molecule, wherein the fluorescent challenge molecule is not substantially absorbed by a healthy gut into the subject's gut, and
b. written instructions for assessing gut function in the subject, comprising the steps of:
i. administering an effective amount of the composition;
ii. irradiating the composition absorbed by the subject's gut with non-ionizing radiation, wherein the radiation causes the fluorescent challenge molecule to fluoresce;
iii. detecting the fluorescence of the composition; and
iv. assessing gut function in the subject based on the detected fluorescence.

### Claim 25

A method of assessing the size of the openings within a subject's gut, comprising the steps of:
a. administering an effective amount of a composition comprising at least one fluorescent challenge molecule, wherein each fluorescent challenge molecule has a different size, and is absorbed by a healthy gut to a different degree into the subject's gut;
b. irradiating the composition absorbed by the subject's gut with non-ionizing radiation, wherein the radiation causes the composition to fluoresce;
c. detecting the fluorescence of each fluorescent challenge molecule in the composition; and
d. assessing the size of the openings within the subject's gut, based on the size of each fluorescent challenge molecule.

### Claim 26 (depends on 25)

The method of claim 25, wherein the size of the challenge molecules absorbed by the subject's gut indicates the minimum size of the openings within the subject's gut.

### Claim 27 (depends on 25)

The method of claim 25, wherein the composition is administered orally.

### Claim 28 (depends on 25)

The method of claim 25, wherein the non-ionizing radiation has a wavelength of at least 350 nm.

### Claim 29 (depends on 25)

The method of claim 25, wherein the composition absorbed by the subject's gut is irradiated and detected in the subject's skin, blood, urine, or fascia.

### Claim 30 (depends on 25)

The method of claim 25, wherein the composition absorbed by the subject's gut is irradiated and detected transcutaneously.
